Cargando…

1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative

BACKGROUND: Adverse drug events are associated with an increase in hospital stay and cost. Risks from these events are minimized by adjusting a medication’s dose or frequency, and changes in renal function may necessitate adjustments. Currently, there is no formal procedure for a prospective audit o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiang Lin, Wei, Binkley, Amanda, Cimino, Christo L, Talati, Naasha J, Mehta, Jimish M, Lamore III, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810997/
http://dx.doi.org/10.1093/ofid/ofz360.938
_version_ 1783462371839180800
author Hsiang Lin, Wei
Binkley, Amanda
Cimino, Christo L
Talati, Naasha J
Mehta, Jimish M
Lamore III, Raymond
author_facet Hsiang Lin, Wei
Binkley, Amanda
Cimino, Christo L
Talati, Naasha J
Mehta, Jimish M
Lamore III, Raymond
author_sort Hsiang Lin, Wei
collection PubMed
description BACKGROUND: Adverse drug events are associated with an increase in hospital stay and cost. Risks from these events are minimized by adjusting a medication’s dose or frequency, and changes in renal function may necessitate adjustments. Currently, there is no formal procedure for a prospective audit of renal function over the weekend at our institution. This pharmacist-driven initiative will evaluate if a prospective review identified by real-time clinical decision support alerts over the weekend will reduce the time from change in renal function to dose adjustment of select antimicrobials and/or anticoagulants. METHODS: This monitoring initiative is comprised of a pre- and post-cohort population. The pre-cohort population included patients admitted to Penn Presbyterian Medical Center (PPMC) from January to March of 2018 on select antimicrobials and/or anticoagulants, who were identified to have a change in renal function (serum creatinine change of 0.3 mg/dL or greater) over the weekend. The post-cohort population was identified with a clinical decision support system (ILÚM Health Solutions, Kenilworth, NJ) and included patients admitted to PPMC from January to March of 2019. A pharmacy resident reviewed alerts in the clinical decision support system over the weekend and contacted providers with dose adjustment recommendations. The Mann–Whitney U test was used to analyze the primary endpoint while descriptive statistics were used for the secondary endpoints RESULTS: Eighteen interventions were completed within the 3-month post-cohort intervention period, with a time to dose adjustment between the pre/post-cohort being reduced by 50 hours (P = 0.0001) resulting in a median time to change of 11 hours in the post-cohort. All pharmacy recommendations were accepted by the provider, and 94% of medication adjustments were antimicrobials. CONCLUSION: The application of this prospective weekend initiative utilizing a clinical decision support system demonstrated a clinically and statistically significant reduction in the time to dose adjustments for antimicrobials and/or anticoagulants. Implementation of this initiative will further establish a role for pharmacist-led evaluations and could potentially be expanded to other clinical areas. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810997
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68109972019-10-28 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative Hsiang Lin, Wei Binkley, Amanda Cimino, Christo L Talati, Naasha J Mehta, Jimish M Lamore III, Raymond Open Forum Infect Dis Abstracts BACKGROUND: Adverse drug events are associated with an increase in hospital stay and cost. Risks from these events are minimized by adjusting a medication’s dose or frequency, and changes in renal function may necessitate adjustments. Currently, there is no formal procedure for a prospective audit of renal function over the weekend at our institution. This pharmacist-driven initiative will evaluate if a prospective review identified by real-time clinical decision support alerts over the weekend will reduce the time from change in renal function to dose adjustment of select antimicrobials and/or anticoagulants. METHODS: This monitoring initiative is comprised of a pre- and post-cohort population. The pre-cohort population included patients admitted to Penn Presbyterian Medical Center (PPMC) from January to March of 2018 on select antimicrobials and/or anticoagulants, who were identified to have a change in renal function (serum creatinine change of 0.3 mg/dL or greater) over the weekend. The post-cohort population was identified with a clinical decision support system (ILÚM Health Solutions, Kenilworth, NJ) and included patients admitted to PPMC from January to March of 2019. A pharmacy resident reviewed alerts in the clinical decision support system over the weekend and contacted providers with dose adjustment recommendations. The Mann–Whitney U test was used to analyze the primary endpoint while descriptive statistics were used for the secondary endpoints RESULTS: Eighteen interventions were completed within the 3-month post-cohort intervention period, with a time to dose adjustment between the pre/post-cohort being reduced by 50 hours (P = 0.0001) resulting in a median time to change of 11 hours in the post-cohort. All pharmacy recommendations were accepted by the provider, and 94% of medication adjustments were antimicrobials. CONCLUSION: The application of this prospective weekend initiative utilizing a clinical decision support system demonstrated a clinically and statistically significant reduction in the time to dose adjustments for antimicrobials and/or anticoagulants. Implementation of this initiative will further establish a role for pharmacist-led evaluations and could potentially be expanded to other clinical areas. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810997/ http://dx.doi.org/10.1093/ofid/ofz360.938 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hsiang Lin, Wei
Binkley, Amanda
Cimino, Christo L
Talati, Naasha J
Mehta, Jimish M
Lamore III, Raymond
1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title_full 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title_fullStr 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title_full_unstemmed 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title_short 1074. Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
title_sort 1074. evaluation of a pharmacist-led antimicrobial and anticoagulant monitoring initiative
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810997/
http://dx.doi.org/10.1093/ofid/ofz360.938
work_keys_str_mv AT hsianglinwei 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative
AT binkleyamanda 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative
AT ciminochristol 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative
AT talatinaashaj 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative
AT mehtajimishm 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative
AT lamoreiiiraymond 1074evaluationofapharmacistledantimicrobialandanticoagulantmonitoringinitiative